Literature DB >> 19777233

Bexarotene: a promising anticancer agent.

Liyan Qu1, Xiuwen Tang.   

Abstract

Retinoids are biologically active derivatives of vitamin A, which play essential roles in embryonic or adult cell behavior modulating cell proliferation, differentiation and apoptosis. The biologic effects of retinoids are mediated by two distinct families of intracellular receptors: retinoid acid receptors (RARs)-α, -β and -γ and retinoid X receptors (RXR)-α, -β and -γ. Bexarotene is a selective RXR agonist, which exerts its effects in blocking cell cycle progression, inducing apoptosis and differentiation, preventing multidrug resistance, and inhibiting angiogenesis and metastasis, making it a promising chemopreventive agent against cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19777233     DOI: 10.1007/s00280-009-1140-4

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

Review 1.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

2.  Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.

Authors:  Neha Mehta; Alan S Wayne; Youn H Kim; Gregory A Hale; Carlos S Alvarado; Patricia Myskowski; Elaine S Jaffe; Klaus J Busam; Melissa Pulitzer; Jeffrey Zwerner; Steven Horwitz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-10-15

3.  Synthesis of 2-Aryl- and 2-Vinylpyrrolidines via Copper-Catalyzed Coupling of Styrenes and Dienes with Potassium β-Aminoethyl Trifluoroborates.

Authors:  Chanchamnan Um; Sherry R Chemler
Journal:  Org Lett       Date:  2016-05-10       Impact factor: 6.005

Review 4.  A review of the molecular design and biological activities of RXR agonists.

Authors:  Nathalia Rodrigues de Almeida; Martin Conda-Sheridan
Journal:  Med Res Rev       Date:  2019-04-03       Impact factor: 12.944

5.  Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents.

Authors:  Lian Chen; Martin Conda-Sheridan; P V Narasimha Reddy; Andrew Morrell; Eun-Jung Park; Tamara P Kondratyuk; John M Pezzuto; Richard B van Breemen; Mark Cushman
Journal:  J Med Chem       Date:  2012-06-19       Impact factor: 7.446

6.  Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain.

Authors:  Geoffrey M Gray; Ning Ma; Carl E Wagner; Arjan van der Vaart
Journal:  J Mol Model       Date:  2017-03-01       Impact factor: 1.810

7.  Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.

Authors:  Jin-Chul Heo; Tae-Hoon Jung; Sungjin Lee; Hyun Young Kim; Gildon Choi; Myungeun Jung; Daeyoung Jung; Heung Kyoung Lee; Jung-Ok Lee; Ji-Hwan Park; Daehee Hwang; Ho Jun Seol; Heeyeong Cho
Journal:  Clin Exp Metastasis       Date:  2016-03-08       Impact factor: 5.150

Review 8.  Targeting truncated RXRα for cancer therapy.

Authors:  Xiaokun Zhang; Hu Zhou; Ying Su
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-10-21       Impact factor: 3.848

9.  Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.

Authors:  Martin Conda-Sheridan; Eun-Jung Park; Daniel E Beck; P V Narasimha Reddy; Trung X Nguyen; Bingjie Hu; Lian Chen; Jerry J White; Richard B van Breemen; John M Pezzuto; Mark Cushman
Journal:  J Med Chem       Date:  2013-03-08       Impact factor: 7.446

10.  DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents.

Authors:  Sebastiano La Maestra; Rosanna T Micale; Silvio De Flora; Francesco D'Agostini; Gancho Ganchev; Marietta Iltcheva; Nikolay Petkov; Vernon E Steele; Roumen Balansky
Journal:  Carcinogenesis       Date:  2012-10-05       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.